Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies

The high primary resistance incidence and unavoidable secondary resistance are the major clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) patients treated with immunotherapy. The mechanisms of immunotherapy resistance in NSCLC are complex, mainly involving tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Suna, Yang, Haihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115980/
https://www.ncbi.nlm.nih.gov/pubmed/37090727
http://dx.doi.org/10.3389/fimmu.2023.1129465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115980/
https://www.ncbi.nlm.nih.gov/pubmed/37090727
http://dx.doi.org/10.3389/fimmu.2023.1129465

Ejemplares similares